CLEC3B and Hypertension: Re-validation of reduced Tetranectin levels was achieved in a second, independent cohort of 224 patients with risk factors (hypertension and/or diabetes) for heart failure (n = 164) or with heart failure (n = 60) using a mass spectrometry approach, designed to target the specific Tetranectin peptide fragment LDTLAQEVALLK.